First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison

Zhu Y, Qi X, Ni S, Qiu W, Chen M

Biologics: Targets and Therapy 2026, 20:602654

Published Date: 28 February 2026